WeHeal
Kaohsiung
About WeHeal
WeHeal develops home electrotherapy devices to help users relieve muscle soreness, improve circulation, and enhance health. Its flagship product, Rehabilitation Force, is a 4-in-1 device that combines transcutaneous electrical nerve stimulation (TENS), electrical muscle stimulation (EMS), bioelectrical impedance (BIA) measurement, and galvanic skin response (GSR) measurement. The device is suitable for post-operative rehabilitation, chronic pain, muscle soreness, and poor peripheral circulation. Users can locate pain points and electrotherapy settings through the exclusive app and use patches for treatment. In addition, WeHeal also provides online instructional videos to assist users in using the device correctly. WeHeal's products have been approved by the Ministry of Health and Welfare of Taiwan for medical device inspection and registration, and a study published in the journal JMIR has confirmed the efficacy of home electrical stimulation therapy in improving the clinical symptoms of ankylosing spondylitis. The company currently only sells its products in Taiwan and does not have a branch in Hong Kong.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.2M
- Funding stage: Seed
- Last round: Seed (Feb 2015)
- Website: weheal.com.tw
- Phone: +886 7-2216313
Industries & Categories
Artificial Intelligence (AI), Health Care, Medical Device
Canonical: https://fsome.com/organization/weheal-3337404 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.